1Duffy MJ.Evidence for the clinical use of tumor markers.Ann Clin Biochem,2004,41 (Pt5):370.
2Nawata S,Murakami A,Torii M,et al.Different expression patterns of intact forms of squamous cell carcinoma antigens between normal and malignant cervical squamous epithelial tissues:nondenaturing polyaorylamide gel electrophoretie analysis.Oncol Pep,2006,16(2):399.
3Shimada Y,Watanabe G,Kawamura J,et al.Clinical significance of osteopontin in esophageal squamous cell carcimoma:comparison with common tumor markers.Oncology,2005,68(2-3):285.
4Molina R,Fileila X,Auge JM,et al.Tumor markers (CEA,CA125,CYFRA21-1,SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis.Comparison with the main clinical aad pathological prognostic factors.Tumonr Biol,2003,24(4):209.
5Ayude D,Gaoio G,et al.Combined use of established and novel tumonr markers in the diagnosis of head and neck squamous cell carcinoma.Oncol Rep,2003,10(5):1345.
6Pras E,Willemas PH,Conrinus AA,et al.Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.Int J Radiat Oncol Biol Plays,2002,52(1):23.
7Takeda M,Sakuragi N,Okamoto K,et al.Preoperative serum SCC,CA125,and CA19-9 levels and lymph node status in equamous cell carcinoma of the uterine cervix.Acta Obstet Gynecol Scand,2002,81 (5):451.
8Ohara K,Tanaka Y,Tsunoda H,et al.Assoesment of cervical cencer radiorespanse by serum squamons cell carcinoma antigen and magnetic resonance imaging.Obstet Gyncol,2002,100(4):781.
9Molina R,Filella X,Auge JM,et al.CYFBA21-1 in patients with cervical cancor:comparison with SCC and CEA.Anticancer Res,2005,25 (3A):1765.
10Yuan CC,Wang PH,Ng HT,et al.Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determinod by a stratification analysis.Eur J Gynancol Oncol,2002,23(1):17.
9Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [ J ]. Int J Cancer, 2010,127:2893-2917.
10Hendrick RE, Smith RA, Rutledge JH, 3rd, et al. Benefit of screening mammography in women aged 40-49 : a new me- ta-analysis of randomized controlled trials [J]. J Natl Cancer Inst Monogr, 1997,22:87-92.
